Zobrazeno 1 - 4
of 4
pro vyhledávání: '"35"'
Autor:
Seiichi Yoshimoto, Hiroshi Igaki, Naoya Murakami, Takao Ueno, Kae Okuma, Kenya Kobayashi, Taisuke Mori, Kana Takahashi, Kimiteru Ito, Yoshitaka Honma, Yuko Nakayama, Jun Itami, Narikazu Boku, Hiroyuki Okamoto, Yuko Kubo, Koji Inaba
Publikováno v:
Journal of Radiation Research
Our previous study by Murakami N, Mori T, Nakamura S, Yoshimoto S, Honma Y, Ueno T, Kobayashi K, Kashihara T, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. (J Radiat Res. 2019 Jul 30. pii: rrz053. doi: 10.1093/jrr/rrz053. [Epub ahead o
Autor:
Susumu Kodaira, Kazuaki Sasaki, Yoshiyuki Yamaguchi, Takayuki Morita, Genichi Nishimura, Sotaro Sadahiro, T. Tsuchiya, Seiji Sato, Hisashi Usuki, Junji Matsuoka, Keiji Koda, Chikuma Hamada, Kenji Katsumata, Ken Kondo, Yoshihiro Kakeji, Hideo Baba
Publikováno v:
Annals of Oncology
While adjuvant chemotherapy is preferable for colon cancer, treatment duration is controversial. This phase III trial is investigated optimal duration of adjuvant chemotherapy for Stage IIB/III colon cancer. Eighteen-month treatment with UFT/LV did n
Autor:
Sylvie Rottey, Desmond Curran, Andrzej Kawecki, Ricard Mesia, Jean-Pierre Delord, Jan B. Vermorken, Ricardo Hitt, D. de Raucourt, Fernando Rivera, Didier Cupissol, Heinz Roland Kienzer, A Gross, Marco Benasso, Carsten Bokemeyer, P. Koralewski
Publikováno v:
Annals of Oncology
Annals of oncology
Annals of oncology
Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the h
Autor:
Fabio M. Iwamoto, Lauren E. Abrey, Wei-Ting Zhang, Susan M. Chang, Howard A. Fine, H. Ian Robins, Michael D. Prados, Minesh P. Mehta, Lisa M. DeAngelis, Kathleen R. Lamborn, Nicholas Butowski
The objective of this phase II single-arm study was to evaluate the efficacy and safety of pazopanib, a multi-targeted tyrosine kinase inhibitor, against vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb622f62cc575442411bdfb2a867e40
https://europepmc.org/articles/PMC2940686/
https://europepmc.org/articles/PMC2940686/